Strongbridge Biopharma (Strongbridge Biopharma) Interest Coverage : 0 (At Loss) (As of Jun. 2021)

View and export this data going back to 2013. Start your Free Trial

What is Strongbridge Biopharma Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Strongbridge Biopharma's Operating Income for the three months ended in Jun. 2021 was $-13.07 Mil. Strongbridge Biopharma's Interest Expense for the three months ended in Jun. 2021 was $-0.81 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Strongbridge Biopharma's Interest Coverage or its related term are showing as below:

SBBP's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Strongbridge Biopharma Interest Coverage Historical Data

The historical data trend for Strongbridge Biopharma's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Strongbridge Biopharma Interest Coverage Chart

Strongbridge Biopharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Interest Coverage

Get a 7-Day Free Trial

N/A

Strongbridge Biopharma Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Strongbridge Biopharma's Interest Coverage

For the Biotechnology subindustry, Strongbridge Biopharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strongbridge Biopharma's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Strongbridge Biopharma's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Strongbridge Biopharma's Interest Coverage falls into.

Strongbridge Biopharma Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Strongbridge Biopharma's Interest Coverage for the fiscal year that ended in Dec. 2020 is calculated as

Here, for the fiscal year that ended in Dec. 2020, Strongbridge Biopharma's Interest Expense was $-1.34 Mil. Its Operating Income was $-43.17 Mil. And its Long-Term Debt & Capital Lease Obligation was $17.78 Mil.

Strongbridge Biopharma did not have earnings to cover the interest expense.

Strongbridge Biopharma's Interest Coverage for the quarter that ended in Jun. 2021 is calculated as

Here, for the three months ended in Jun. 2021, Strongbridge Biopharma's Interest Expense was $-0.81 Mil. Its Operating Income was $-13.07 Mil. And its Long-Term Debt & Capital Lease Obligation was $17.00 Mil.

Strongbridge Biopharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's Financial Strength is.

Strongbridge Biopharma (NAS:SBBP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Strongbridge Biopharma Interest Coverage Related Terms

Thank you for viewing the detailed overview of Strongbridge Biopharma's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Strongbridge Biopharma (Strongbridge Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Strongbridge Biopharma PLC (NAS:SBBP) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

900 Northbrook Drive, Suite 200, Trevose, PA, USA, 19053

Website

http://www.strongbridgebio.com

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.

Executives

David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Cdk Associates, L.l.c.	10 percent owner	C/O CAXTON CORPORATION, 731 ALEXANDER ROAD, BUILDING #2, PRINCETON NJ 08540
Bruce Kovner	10 percent owner	C/O CAXTON ASSOCIATES, 500 PARK AVENUE, NEW YORK NY 10022
Caxton Corp	10 percent owner	731 ALEXANDER ROAD, BUILDING 2, SUITE 500, PRINCETON NJ 08540
John Johnson	director, officer: Chief Executive Officer	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Garheng Kong	director	712 COLLEGE AVENUE, MENLO PARK CA 94025
Jeffrey W Sherman	director	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Marten Steen	director	60 LEVERONI COURT, NOVATO CA 94949
Hilde H Steineger	director	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Stephen J Long	officer: Chief Legal Officer	C R BARD INC 730 CENTRAL AVENUE MURRAY HILL NJ 07974
Fredric J. Cohen	officer: Chief Medical Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Scott L. Wilhoit	officer: Chief Commercial Officer	900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053
Robert Matthew Lutz	officer: Chief Financial Officer	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Richard S Kollender	officer: Chief Operating Officer	C/O QUAKER BIOVENTURES, CIRA CENTRE, 2929 ARCH STREET, 3RD FLOOR, PHILADELPHIA PA 19104-2868
A Brian Davis	officer: Chief Financial Officer	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380